BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 18067207)

  • 1. Increased levels of tumor markers in the follow-up of 400 patients with breast cancer without recurrence or metastasis: interpretation of false-positive results.
    Zervoudis S; Peitsidis P; Iatrakis G; Panourgias E; Koureas A; Navrozoglou I; Dubois JB
    J BUON; 2007; 12(4):487-92. PubMed ID: 18067207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients.
    Giai M; Roagna R; Ponzone R; Biglia N; Sgro L; Perona M; Sismondi P
    Anticancer Res; 1996; 16(2):875-81. PubMed ID: 8687144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [CA 15-3 and CEA as tumor markers in the diagnosis of the recurrence of breast cancer].
    Engel K; Schmid H; Hanke J; Kaufmann M; Müller A
    Geburtshilfe Frauenheilkd; 1988 May; 48(5):309-12. PubMed ID: 3165077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [MCA and CA 15-3 in the follow-up of patients with breast cancer].
    Hammer J; Track C; Hohenwallner W; Seewald DH; Zoidl JP; Wimmer E
    Strahlenther Onkol; 1992 Feb; 168(2):102-6. PubMed ID: 1542844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Study for clinical usefulness of CEA, TPA, CA15-3 and BCA225 in breast cancer].
    Kaneko Y; Imoto S; Kasakura S
    Rinsho Byori; 1995 Jul; 43(7):696-702. PubMed ID: 7674542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of serum tumor markers TPS and CA 15-3 during monitoring of treatment in metastatic breast cancer patients.
    Schuurman JJ; Bong SB; Einarsson R
    Anticancer Res; 1996; 16(4B):2169-72. PubMed ID: 8694538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical usefulness of tumor markers in breast cancer].
    Konishi K; Karaki K; Watanabe K; Tsuda H; Konishi F
    Rinsho Byori; 1993 Oct; 41(10):1108-15. PubMed ID: 8254956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Initial experiences with CA-15-3 determination in the serum of patients with breast cancer].
    Bartel U; Johannsen B; Reiss H; Elling D
    Zentralbl Gynakol; 1989; 111(21):1417-24. PubMed ID: 2557715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. False elevation of serum CA 15-3 levels in patients under follow-up for breast cancer.
    Aguiar-Bujanda D; Bohn-Sarmiento U; Aguiar-Morales J
    Breast J; 2004; 10(4):375-6. PubMed ID: 15239804
    [No Abstract]   [Full Text] [Related]  

  • 10. [The tumor markers TPA and CEA in the after care of breast cancer].
    Beaufort F; Fueger GF; Steiner H
    Wien Med Wochenschr; 1985 Feb; 135(4):85-8. PubMed ID: 2986366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical value of CYFRA 8/18 and TPS in the diagnosis and follow up of invasive breast cancer.
    Sütterlin M; Oehler MK; Caffier H
    Anticancer Res; 1997; 17(4B):2963-5. PubMed ID: 9329576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Considerations in rational use of tumor markers in breast carcinoma].
    Crombach G
    Praxis (Bern 1994); 1998 Apr; 87(17):589-94. PubMed ID: 9623326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor markers in breast cancer.
    Tondini C; Hayes DF; Kufe DW
    Hematol Oncol Clin North Am; 1989 Dec; 3(4):653-74. PubMed ID: 2691493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients.
    Gion M; Peloso L; Mione R; Vignati G; Fortunato A; Saracchini S; Biasioli R; Gulisano M; Cappelli G
    Cancer J; 2001; 7(3):181-90. PubMed ID: 11419026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relapse and survival in early-stage ovarian cancer.
    Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
    Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of serum CEA, PHI, and TPA as tumor markers in breast cancer patients.
    Paulick R; Caffier H; Paulick M
    Cancer Detect Prev; 1987; 10(3-4):197-203. PubMed ID: 3568016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tumor markers in the early diagnosis of recurrence in gynecologic neoplasms: combined determination of CA-125, CA 15-3, CA 72.4, SCC, 90 K].
    Garzetti GC; Di Lauro RM; Ciavattini A; Pallotta MR; Marchegiani F; Valensise H; Tranquilli AL; Arduini D; Romanini C
    Ann Ostet Ginecol Med Perinat; 1991; 112(5):320-3. PubMed ID: 1817444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pre- and post-therapeutic serum concentrations of mucin-like carcinoma-associated antigen in patients with breast cancer].
    Fuith LC; Artner-Dworzak E; Schröcksnadel H; Müller-Holzner E; Daxenbichler G; Heim K
    Gynakol Rundsch; 1989; 29 Suppl 2():397-9. PubMed ID: 2613061
    [No Abstract]   [Full Text] [Related]  

  • 19. Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients.
    Laessig D; Nagel D; Heinemann V; Untch M; Kahlert S; Bauerfeind I; Stieber P
    Anticancer Res; 2007; 27(4A):1963-8. PubMed ID: 17649806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence.
    Marques AR; Teixeira E; Diamond J; Correia H; Santos S; Neto L; Ribeiro M; Miranda A; Passos-Coelho JL
    Breast Cancer Res Treat; 2009 Mar; 114(2):223-32. PubMed ID: 18409061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.